Peraldo-Neia C - Search Results

1

Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.

Montemurro F, Prat A, Rossi V, Valabrega G, Sperinde J, Peraldo-Neia C, Donadio M, Galván P, Sapino A, Aglietta M, Baselga J, Scaltriti M. Montemurro F, et al. Mol Oncol. 2014 Feb;8(1):20-6. doi: 10.1016/j.molonc.2013.08.013. Epub 2013 Sep 13. Mol Oncol. 2014. PMID: 24075779 Free PMC article. Clinical Trial.

2

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.

Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F. Valabrega G, et al. Breast Cancer Res Treat. 2011 Nov;130(1):29-40. doi: 10.1007/s10549-010-1281-5. Epub 2010 Dec 9. Breast Cancer Res Treat. 2011. PMID: 21153051

3

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer.

Peraldo-Neia C, Migliardi G, Mello-Grand M, Montemurro F, Segir R, Pignochino Y, Cavalloni G, Torchio B, Mosso L, Chiorino G, Aglietta M. Peraldo-Neia C, et al. BMC Cancer. 2011 Jan 25;11:31. doi: 10.1186/1471-2407-11-31. BMC Cancer. 2011. PMID: 21266046 Free PMC article.

4

Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma.

Cavalloni G, Peraldo-Neia C, Varamo C, Chiorino G, Sassi F, Aglietta M, Leone F. Cavalloni G, et al. Oncotarget. 2016 Aug 9;7(32):52354-52363. doi: 10.18632/oncotarget.10587. Oncotarget. 2016. PMID: 27429047 Free PMC article.

5

Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line.

Peraldo Neia C, Cavalloni G, Chiorino G, Ostano P, Aglietta M, Leone F. Peraldo Neia C, et al. Oncotarget. 2016 Dec 27;7(52):86766-86780. doi: 10.18632/oncotarget.13575. Oncotarget. 2016. PMID: 27902465 Free PMC article.

6

Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR.

Peraldo-Neia C, Cavalloni G, Fenocchio E, Cagnazzo C, Gammaitoni L, Cereda S, Nasti G, Satolli MA, Aprile G, Reni M, Avallone A, Spadi R, Venesio T, Martin V, Doglioni C, Frattini M, Aglietta M, Leone F. Peraldo-Neia C, et al. PLoS One. 2018 Jan 19;13(1):e0191593. doi: 10.1371/journal.pone.0191593. eCollection 2018. PLoS One. 2018. PMID: 29352306 Free PMC article. Clinical Trial.

7

Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR.

Peraldo Neia C, Cavalloni G, Balsamo A, Venesio T, Napoli F, Sassi F, Martin V, Frattini M, Aglietta M, Leone F. Peraldo Neia C, et al. Genes Chromosomes Cancer. 2014 Dec;53(12):1033-40. doi: 10.1002/gcc.22212. Epub 2014 Sep 18. Genes Chromosomes Cancer. 2014. PMID: 25231053

8

Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma.

Massa A, Peraldo-Neia C, Vita F, Varamo C, Basiricò M, Raggi C, Bernabei P, Erriquez J, Sarotto I, Leone F, Marchiò S, Cavalloni G, Aglietta M. Massa A, et al. Among authors: peraldo neia c. Front Oncol. 2022 Feb 17;12:771418. doi: 10.3389/fonc.2022.771418. eCollection 2022. Front Oncol. 2022. PMID: 35251961 Free PMC article.

9

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.

Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, Casorzo L, Chiorino G, Risio M, Bardelli A, Aglietta M, Leone F. Pignochino Y, et al. BMC Cancer. 2010 Nov 18;10:631. doi: 10.1186/1471-2407-10-631. BMC Cancer. 2010. PMID: 21087480 Free PMC article.

10

Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas.

Cavalloni G, Peraldo-Neia C, Sarotto I, Gammaitoni L, Migliardi G, Soster M, Marchiò S, Aglietta M, Leone F. Cavalloni G, et al. Mol Cancer Ther. 2012 Jul;11(7):1528-38. doi: 10.1158/1535-7163.MCT-11-1020. Epub 2012 Mar 27. Mol Cancer Ther. 2012. PMID: 22452946

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

28 results

Search Page